Divergent Role of Statin Use and Intensity in Patients Undergoing Transcatheter Aortic Valve Replacement

Figures

• 

  Fig. 1.. Flowchart – dual-arm longitudinal cohort study design. AS, aortic stenosis; TAVR, transcatheter aortic valve replacement; AKI, acute kidney injury; eGFR, estimated glomerular filtration rate; LMIS, low-to-moderate-intensity statin; HIS, high-intensity statin; Scr, serum creatinine.

• 

  Fig. 2.. Thirty-day change in renal function (GFR) by statin use and statin intensity following TAVR. a 30-Day post-TAVR glomerular filtration rate status stratified by statin use (no statin vs. statin). b GFR changes stratified by statin intensity (low-to-moderate-intensity statins [LMIS] vs. high-intensity statins [HIS]).

• 

  Fig. 3.. Cumulative incidence of acute kidney injury (AKI) within 30 days after TAVR stratified by statin use and intensity. a Cumulative incidence of AKI comparing patients receiving any statin therapy vs. no statin therapy. b Cumulative incidence of AKI stratified by statin intensity: low-to-moderate-intensity statins (LMIS) vs. high-intensity statins (HIS). Shaded areas represent 95% confidence intervals. Numbers at risk are shown below each graph.

• 

  Fig. 4.. Adjusted multinomial regression models for 30-day eGFR change after TAVR. a Statin-use arm: relative risk ratios (RRRs) with 95% confidence intervals for improved vs. stable and deteriorated vs. stable eGFR at 30 days, adjusted for baseline and procedural covariates. b Statin-intensity arm: relative risk ratios (RRRs) with 95% confidence intervals comparing high-intensity vs. low-to-moderate-intensity statins, additionally adjusted for statin adherence. CI, confidence interval; eGFR, estimated glomerular filtration rate; HIS, high-intensity statin; LMIS, low-to-moderate-intensity statin; PVD, peripheral vascular disease; RRR, relative risk ratio; SEV, self-expanding valve; BEV, balloon-expandable valve.